Abstracts tagged "autoimmune diseases"

Abstract Number: 0248 • ACR Convergence 2025
Clinical and serological characteristics of anti-Ku autoantibodies in a Hispanic cohort
Emmanuel Dominguez-Chapa¹, Angel Kevin Garza-Elizondo², Karina Deciderio-Pavon³, Rosa Arvizu-Rivera⁴, Jesus Alberto Cardenas-de la Garza⁵, Miguel Villarreal-Alarcón⁶ and Dionicio A. Galarza-Delgado⁷, ¹Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo Leon, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Nuevo León, Mexico, ⁵Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁶Hospital Universitario UANL, Monterrey, Nuevo León, Mexico, ⁷Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Anti-Ku antibodies are rare myositis-associated antibodies directed against a DNA-binding heterodimer involved in DNA repair. Anti-Ku positivity may be associated with a distinct clinical…
Abstract Number: 0157 • ACR Convergence 2025
Influence of Outpatient Clinic Visits on Receipt of the COVID-19 Vaccine among People with Autoimmune Rheumatic Diseases
Lesley Jackson¹, Nicole Wright², Rahima Begum³, Fazlur Rahman¹, Rena Patel¹, Kenneth Saag⁴, Jeffrey Curtis⁵ and Maria I. ("Maio") Danila⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²Tulane University School of Medicine, New Orleans, LA, ³University of Alabama at Birmingham, Birmingham, ⁴The University of Alabama at Birmingham, Birmingham, AL, ⁵Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ⁶University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Rheumatologists and primary care providers (PCPs) are some of the most trusted clinicians for people living with autoimmune rheumatic diseases (AIRD), and they may…
Abstract Number: 0029 • ACR Convergence 2025
A Novel B Cell Subpopulation Characteristic of IgA Vasculitis Identified by Single-Cell RNA Sequencing
Joao Carlos Batista-Liz¹, María Sebastián Mora-Gil², Evan Troendle³, Oisin Cappa³, Maite Leonardo⁴, Ana Peñalba⁴, Luis mARTIN pENAGOS⁵, Ligia Gabrie-Rodriguez⁶, Rafael Gálvez Sánchez⁶, Jose Luis Callejas⁷, Belen Sevilla⁸, Diego de Argila⁹, Esther Vicente-Rabaneda⁹, Santos Castañeda¹⁰, David Simpson³, Ricardo Blanco¹¹, Verónica Pulito Cueto¹ and Raquel Lopez Mejias¹, ¹IDIVAL, Santander, Spain, ²Immunopathology Group, IDIVAL, Santander, Spain, ³Queens University, Wellcome-Wolfson Institute for Experimental Medicine, Belfast, United Kingdom, ⁴Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Immunopathology Group, IDIVAL and Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁷Department of Internal Medicine, Hospital San Cecilio, Granada, Spain, ⁸Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ⁹Hospital Universitario de la Princesa, Madrid, Spain, ¹⁰Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: IgA vasculitis (IgAV) is a systemic small-vessel vasculitis characterized by immune complex deposition containing aberrantly glycosylated IgA1. While its clinical manifestations are well defined…
Abstract Number: 2460 • ACR Convergence 2025
Comparative Efficacy of Belimumab, Anifrolumab, and Rituximab in SLE: A Retrospective Analysis of Serological and Clinical Outcomes
Pablo Martínez Calabuig¹, Jorge Juan Fragío Gil², Roxana González Mazario³, Laura Salvador Maicas⁴, Mireia Sanmartin Martínez⁴, Iván Jesús Lorente Betanzos⁴, Amalia Rueda Cid⁴, Juan José Lerma Garrido⁴, Isabel Martínez Cordellat⁴, Isabel Balaguer Trull⁴, Berta Gómez Correas⁴ and Cristina Campos Fernández³, ¹Hospital General Universitario de Valencia, Spain/ Uversidad Catolica de Valencia San Vicente Martir, Valencia, Spain, Ontinyent, Spain, ²Hospital General Universitario, Valencia, Spain, ³Hospital General de Valencia, Valencia, Spain, ⁴Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with multisystem involvement and fluctuating activity. Biologic therapies such as Belimumab, Anifrolumab, and Rituximab offer…
Abstract Number: 2658 • ACR Convergence 2025
Risk of Immune-Mediated Inflammatory Diseases and Other Safety Outcomes in Patients with T2DM and Obesity Initiating GLP-1 RA: A Propensity Score-Matched Multi-center Study using the TriNetX Global Network
Hsin-Hua Chen and Wen-Cheng Chao, Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China)
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes mellitus (T2DM) and obesity due to their beneficial metabolic effects. However,…
Abstract Number: 2549 • ACR Convergence 2025
Perceived Dignity in Patients With Rheumatic Disease
Andres M. Ortiz-Rios¹, Braulio R. Avalos-Garcia¹, Fany Rocio Arevalo-Nieto¹, Maria Eugenia Corral-Trujillo², Tania Sarahi Ayala-Garcia¹, David Alejandro Ramirez-Cantu¹, Leonardo Uriel Tapia-Aguayo¹, Jesus Mario Ortiz-Palafox³, Dunja Athalia Perez-Garfias¹, Jesus Alberto Cardenas-de la Garza⁴, Lorena Perez-Barbosa¹, Dionicio A. Galarza-Delgado⁵ and Cassandra M. Skinner-Taylor¹, ¹Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Universidad Autónoma de Nuevo León, Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México., Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterey, Nuevo Leon, Mexico, ⁴Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁵Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Human dignity is an inherent value for all individuals. In healthcare, dignity is often referred to as perceived dignity, which encompasses the value and…
Abstract Number: 2421 • ACR Convergence 2025
Whole Blood Immune Phenotyping Reveals Cytometric Differences in B Cell Clusters Between Lupus Nephritis and Non-Lupus Nephritis SLE Patients with Minimal Proteinuria
Nicholas Bauer¹, Philip Carlucci², Rufei Lu¹, Carla Guthridge¹, Tayte Stephens³, Benjamin Jones⁴, Wade DeJager⁵, Susan Macwana¹, Andrea Fava⁶, Sanchit Sanyal⁷, Erin Carter⁸, Mala Masson⁹, Jennifer Anolik¹⁰, Jennifer Barnas¹¹, Peter Izmirly¹², H Michael Belmont¹³, Kelly Ruggles¹⁴, Study Team ALE⁰⁶ Clinical¹, Brad Rovin¹⁵, Jill Buyon¹⁶, Michelle Petri¹⁷, Judith James¹ and Joel Guthridge¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²New York University School of Medicine, New York, NY, ³University of Oklahoma Health Science Center, Oklahoma City, OK, ⁴Oklahoma State University, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, Oklahoma City, ⁶Johns Hopkins University, Baltimore, MD, ⁷Johns Hopkins University School of Medicine, Baltimore, MD, ⁸New York University Grossman School of Medicine, New York, NY, ⁹NYU Langone Medical Center- Division of Rheumatology, New York, NY, ¹⁰University of Rochester Medical Center, Rochester, NY, ¹¹University of Rochester, Rochester, NY, ¹²New York University Grossman School of Medicine, New York, NY, ¹³NYU School of Medicine, New York, NY, ¹⁴NYU Grossman School of Medicine, Brooklyn, NY, ¹⁵The Ohio State University, Columbus, OH, ¹⁶NYU Grossman School of Medicine, New York, NY, ¹⁷Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Autoreactive B cell populations play a key role in the pathogenesis of lupus nephritis (LN). Therefore, it is hypothesized that dysregulation in the B…
Abstract Number: 2171 • ACR Convergence 2025
Knowledge of Fertility and Infertility Treatments Among Physicians Treating Women with Rheumatic Diseases: FIT-KS Survey
Andres M. Ortiz-Rios¹, Mara Alejandra Ponce-Santillan¹, Braulio R. Avalos-Garcia¹, Eva Abigaid Galindo-Calvillo¹, Carolina Treviño-Sanchez¹, Samantha Lynn Salinas-Rodriguez¹, Arantza Michelle Núñez-Elizondo², Erendira Berenice Noyola-Sauceda¹, Guadalupe Valentina Vazquez-Guerra¹, Jesus Alberto Cardenas-de la Garza³, Lorena Perez-Barbosa¹, Dionicio A. Galarza-Delgado⁴ and Cassandra Michele Skinner-Taylor¹, ¹Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Universidad Autónoma de Nuevo León, Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México., Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁴Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Rheumatic diseases frequently affect individuals of reproductive age, and up to 40–70% may experience fertility issues related to disease activity, medications, delayed childbearing, and…
Abstract Number: 1875 • ACR Convergence 2025
Fcγ-receptor activation by circulating immune complexes in autoimmunity and CD19.CAR-T cell therapy
Merle Freitag¹, Maren Claus², Philippe Kolb³, Valeria Falcone⁴, Ivana Andreeva¹, Norbert Blank⁵, Hanns-Martin Lorenz⁶, Georg Schett⁷ and Wolfgang Merkt⁸, ¹Uniklinik Heidelberg, Heidelberg, Germany, ²IfADo, Leibniz Institute Dortmund, Dortmund, Germany, ³INSTITUTE OF VIROLOGY Medical Center, Freiburg, Freiburg, Germany, ⁴University Medical Center, Freiburg, Freiburg, Germany, ⁵University Hospital Heidelberg, Heidelberg, Germany, ⁶Universitétsklinikum Heidelberg, Heidelberg, Germany, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸University Hospital Düsseldorf, Düsseldorf, Germany
Background/Purpose: The role of autoantibodies in systemic autoimmunity, such as connective tissue diseases (CTD), has been recently highlighted by the successful treatment with CD19-targeting CAR-T…
Abstract Number: 1730 • ACR Convergence 2025
Oral glucocorticoid treatment for checkpoint inhibitor associated inflammatory arthritis do not affect progression free survival: a RADIOS Registry cohort study
Deanna Jannat-Khah¹, Pankti Reid², Maria Suarez-Almazor³, Noha Abdel-Wahab⁴, Jeffrey Sparks⁵, Tawnie Braaten⁶, Cassandra Calabrese⁷, Alexa Meara⁸, Minerva Nong⁹, Kyle Ge¹⁰, Laura Cappelli¹¹, Ami Shah¹², Clifton Bingham¹³ and Anne R. Bass¹, ¹Hospital For Special Surgery, New York, NY, ²University of Chicago Medical Center, Chicago, IL, ³MD Anderson Cancer Center, Houston, TX, ⁴University of Texas MD Anderson Cancer Center, houston, TX, ⁵Brigham and Women's Hospital, Boston, MA, ⁶UNIVERSITY OF UTAH, Salt Lake City, UT, ⁷Cleveland Clinic Foundation, Cleveland Heights, OH, ⁸The Ohio State University Wexner Medical Center, COLUMBUS, OH, ⁹Columbia University, New York, ¹⁰Hospital for Special Surgery, New York, ¹¹Johns Hopkins School of Medicine, Baltimore, MD, ¹²Johns Hopkins Rheumatology, Baltimore, MD, ¹³Johns Hopkins University, Baltimore, MD
Background/Purpose: As immune checkpoint inhibitor (ICI) usage increases for various cancers the prevalence of rheumatologic immune related adverse events (irAEs) also grows. Glucocorticoids are first…
Abstract Number: 1549 • ACR Convergence 2025
Improvement in Joint Activity in Adults with Systemic Lupus Erythematosus Treated with Anifrolumab: Results from a Real-World Cohort
Vasileios Kyttaris¹, Dan Persons², Gelareh Atefi³ and Mawuena Binka⁴, ¹Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, ²Trio Health, Louisville, CO, ³AstraZeneca, Wilmington, DE, ⁴Former Employee of AstraZeneca, Wilmington, DE
Background/Purpose: Inflammatory arthritis is a cardinal manifestation of systemic lupus erythematosus (SLE), limiting joint mobility and adversely affecting quality of life.1 Joint activity in SLE…
Abstract Number: 1441 • ACR Convergence 2025
Efficacy and Safety of Vunakizumab in Patients with Active Ankylosing Spondylitis by Cigarette Smoking Status: A Post Hoc Analysis of a Randomized, Double-blind, Phase 2/3 Study
Hongbin Li¹ and Huilin Li², ¹Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Nei Mongol, China (People's Republic), ²Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China (People's Republic)
Background/Purpose: Vunakizumab, a humanized anti-interleukin-17A monoclonal antibody, has shown significant efficacy and favorable safety in patients with active ankylosing spondylitis (AS), leading to its approval…
Abstract Number: 1277 • ACR Convergence 2025
Combination Therapy with Rituximab and Cyclophosphamide for Treating Pediatric Patients with Severe Manifestations of Rheumatic Disease
Eileen Rife¹, Daniel Reiff², John Bridges³, Emily Smitherman¹, randy Cron¹, Matthew Stoll¹, Melissa Mannion¹, Peter Weiser⁴ and Livie Timmerman⁵, ¹University of Alabama at Birmingham, birmingham, AL, ²Boys Town Hospital, Omaha, ³University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL, ⁴University of Alabama at Birmingham, Birmingham, ⁵University of Alabama at Birmingham, Gardendale, AL
Background/Purpose: Current practice guidelines recommend either rituximab (RTX) or cyclophosphamide (CYC) for treatment of organ-threatening manifestations of systemic vasculitis or connective tissue disease (e.g., diffuse…
Abstract Number: 1151 • ACR Convergence 2025
A Comparison of Patients with Cardiac Sarcoidosis vs. Other Systemic Manifestations of Sarcoidosis: A Retrospective Cohort Study
Chelsea Guan¹, Dana Nachawati¹, Amir Daneshvar¹, Keri Ann Pfeil¹, Elleson Harper¹, Lindsay Frumker², Meghan Gump¹, Vicky Nahra³ and Omer Pamuk⁴, ¹University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ²University hospitals Cleveland medical center, Highland Heights, OH, ³University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland Heights, OH, ⁴University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Sarcoidosis is a systemic autoimmune disease with multiorgan involvement. In this study, we analyzed the differences in characteristics in patients with sarcoid myocarditis (cardiac…
Abstract Number: 0991 • ACR Convergence 2025
MTHFD2 is a Novel Metabolic Target in Autoimmune Disease
Laura McMillan, Celia Evans, Marina Makrecka-Kuka, Niamh Richmond, Gareth Davies, Hamel Patel, Michael Herdman, Mark Whitmarsh, Alessandro Mazzacani, Peter Bunyard, Madduri Ravin Rao and Iain Kilty, Sitryx Therapeutics, Oxford, United Kingdom
Background/Purpose: Aberrant activation and persistence of adaptive immune responses play a central role in autoimmune pathogenesis. Where traditional immunosuppressive therapies offer a broad targeting approach,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].